Final results from the phase 3 OPTIMAL trial showed that patients with mutant type epidermal growth factor receptor (EGFR) showed significant overall survival (OS) benefit when treated with EGFR and tyrosine-kinase inhibitor (TKI) erlotinib.
The study suggested that erlotinib should be considered standard first-line treatment for EGFR mutant patients with non-small cell lung cancer (NSCLC), stated an article published online ahead of print in the Annals of Oncology.
The OPTIMAL study compared the efficacy and tolerability of EGFR-TKI erlotinib versus standard chemotherapy in first-line treatment of patients with EGFR mutation-positive advanced NSCLC.
Out of 165 randomized patients, 82 received erlotinib and 72 gemcitabine plus carboplatin. Final analyses were performed following the death of 70% of patients in the intent-to-treat population.
There were no significant between-group differences in the overall population, the exon 19 deletion subpopulation, or the exon 21 L858 mutation population.
Those who received sequential combination of EGFR-TKI with chemotherapy had significant improvement in OS compared with those who received either monotherapy with EGFR-TKI or chemotherapy (29.7 months, 20.7, and 11.2, respectively).
- Zhou C, Wu YL, Chen G, et al. Final overall survival results from a randomized, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small cell lung cancer (OPTIMAL, CTONG-0802). Annals of Oncol. [epub ahead of print]. doi: 10.1093/annonc/mdv276.